Rx for Biotech Podcast Por Podcast Host Chris Leidli arte de portada

Rx for Biotech

Rx for Biotech

De: Podcast Host Chris Leidli
Escúchala gratis

The Rx for Biotech podcast is focused on the promise of advanced therapies and the leaders across the healthcare ecosystem bringing these innovative medicines to patients in need. The podcast features interviews with the experts who are developing advanced therapies and AI-powered health technologies including physicians, healthcare providers, patient advocates, and technology leaders. To learn more about Advanced Therapies, visit our Knowledge Base: https://www.advancedtherapiesconnect.ai/knowledge-base To find a specialist at an advanced therapy treatment center, visit our Advanced Therapy AI-powered referral tool here: https://www.advancedtherapiesconnect.ai/ To learn more about Genoplex, please visit https://www.genoplex.aiAll rights reserved Economía
Episodios
  • The Future of Precision Medicine: How Biomarkers Can Guide Your Treatment
    Mar 24 2026
    What if a simple blood test could reveal how your body responds to disease - or even help doctors choose the right treatment for you? In this episode of Rx for Biotech, host Chris Leidli speaks with Mo Jain, MD, PhD, co-founder of Sapient, about how scientists are using advanced biology and artificial intelligence to uncover new biomarkers - the biological signals that can help doctors understand what’s happening inside the body. Biomarkers are becoming one of the most important tools in precision medicine, helping physicians move beyond one-size-fits-all treatments toward care that is tailored to each patient’s unique biology. Mo explains how Sapient is analyzing thousands of human samples using advanced technologies to better understand metabolism, disease progression, and how patients respond to therapies. These insights could help improve early diagnosis, guide treatment decisions, and empower patients with more personalized health information. In this conversation, you’ll learn: • What biomarkers are and why they matter for patients • How AI and advanced biology are helping scientists discover new health insights • Why understanding your body’s metabolism can change how diseases are treated • How biomarker data could help patients and doctors make better care decisions As medicine becomes more personalized, having the right biological information may become one of the most powerful tools patients have to advocate for their own care. For additional patient education and support, visit: https://therapy4me.ai
    Más Menos
    41 m
  • How Novartis is Changing Cancer Treatment and Putting Patients First in Modern Cancer Care
    Mar 12 2026
    In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan). We discuss: * How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells * The role of innovation in advanced and metastatic prostate cancer * Expanding patient access to cutting-edge therapies * Why patient advocacy and education matter in modern oncology As prostate cancer remains one of the most common cancers in men, new treatment approaches like radioligand therapy are redefining what’s possible for patients living with advanced prostate cancer.
    Más Menos
    27 m
  • Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases
    Feb 11 2026
    What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer’s? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease. Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.
    Más Menos
    33 m
Todavía no hay opiniones